Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.

Autor: Metts JL; Sarcoma Department, Moffitt Cancer Center, Tampa, Florida, USA.; Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA., Aye JM; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA., Crane JN; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Pediatrics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Oberoi S; Department of Pediatric Hematology/Oncology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada.; Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada., Balis FM; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Bhatia S; Institute for Cancer Outcomes and Survivorship, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA., Bona K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Carleton B; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Dasgupta R; Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA., Dela Cruz FS; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Greenzang KA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kaufman JL; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.; Patient Advocacy Committee, Children's Oncology Group, Monrovia, California, USA., Linardic CM; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA., Parsons SK; Institute for Clinical Research and Health Policy Studies and Division of Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts, USA., Robertson-Tessi M; Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Rudzinski ER; Department of Laboratory Medicine and Pathology, Seattle Children's Hospital and University of Washington Medical Center, Seattle, Washington, USA., Soragni A; Department of Orthopedic Surgery, University of California Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA., Stewart E; Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA., Weigel BJ; Division of Pediatric Hematology Oncology, University of Minnesota, Minneapolis, Minnesota, USA., Wolden SL; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Weiss AR; Department of Pediatrics, Maine Medical Center, Portland, Maine, USA., Venkatramani R; Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA., Heske CM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2024 Nov 15; Vol. 130 (22), pp. 3785-3796. Date of Electronic Publication: 2024 Jun 28.
DOI: 10.1002/cncr.35457
Abstrakt: Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements in understanding the biology and clinical behavior of RMS have led to more nuanced approaches to diagnosis, risk stratification, and treatment. The complexities introduced by these advancements, coupled with the rarity of RMS, pose challenges to conducting large-scale phase 3 clinical trials to evaluate new treatment strategies for RMS. Given these challenges, systematic planning of future clinical trials in RMS is paramount to address pertinent questions regarding the therapeutic efficacy of drugs, biomarkers of response, treatment-related toxicity, and patient quality of life. Herein, the authors outline the proposed strategic approach of the Children's Oncology Group Soft Tissue Sarcoma Committee to the next generation of RMS clinical trials, focusing on five themes: improved novel agent identification and preclinical to clinical translation, more efficient trial development and implementation, expanded opportunities for knowledge generation during trials, therapeutic toxicity reduction and quality of life, and patient engagement.
(© 2024 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: